Literature DB >> 21418393

Expression of KITENIN in human colorectal cancer and its relation to tumor behavior and progression.

Seok Lee1, Young-A Song, Young-Lan Park, Sung-Bum Cho, Wan-Sik Lee, Jae-Hyuk Lee, Ik-Joo Chung, Kyung-Keun Kim, Jong-Sun Rew, Young-Eun Joo.   

Abstract

KAI1 COOH-terminal interacting tetraspanin (KITENIN) contributes to tumor invasion and metastasis in various cancers. The aim of current study was to evaluate whether KITENIN affects tumor cell invasion and prognosis in human colorectal cancers. We investigated the biologic role of KITENIN on tumor cell invasion by using small interfering RNA in Caco2, DLD1, and SW480. We evaluated the expression of KITENIN and activator protein-1 (AP-1) target genes in human colorectal cancer tissues. The tumor cell invasion was decreased by knockdown of KITENIN in three tested cell lines. The mRNA expression of cyclin D1 and COX-2 was decreased in KITENIN knockdown Caco2 and the mRNA expression of MMP-3 and COX-2 was decreased in KITENIN knockdown DLD1 and SW480. The extracellular-signal protein kinase 1/2 (ERK1/2) phosphorylation was decreased in KITENIN knockdown in three tested cell lines. Expression of KITENIN and AP-1 target genes was significantly increased in human colorectal cancer tissues. The ERK1/2, c-Jun N-terminal kinase (JNK) and p38 phosphorylations were increased in human colorectal cancer tissues. Expression of KITENIN was significantly associated with lymphovascular invasion, depth of invasion, lymph node metastasis, tumor stage and poor survival. These results indicate that KITENIN is associated with human colorectal cancer progression including invasion and metastasis.
© 2011 The Authors. Pathology International © 2011 Japanese Society of Pathology and Blackwell Publishing Asia Pty Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21418393     DOI: 10.1111/j.1440-1827.2011.02646.x

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  7 in total

1.  Downregulation of VANGL1 inhibits cellular invasion rather than cell motility in hepatocellular carcinoma cells without stimulation.

Authors:  Gokhan Ozan Cetin; Asli Toylu; Nese Atabey; Zeynep Sercan; Meral Sakizli
Journal:  Genet Test Mol Biomarkers       Date:  2015-04-15

2.  A peptide interfering with the dimerization of oncogenic KITENIN protein and its stability suppresses colorectal tumour progression.

Authors:  Sung Jin Kim; Eun Gene Sun; Jeong A Bae; Sehoon Park; Chang-Soo Hong; Zee-Yong Park; Hangun Kim; Kyung Keun Kim
Journal:  Clin Transl Med       Date:  2022-07

3.  Phosphorylated p38, a negative prognostic biomarker, complements TNM staging prognostication in colorectal cancer.

Authors:  Xin-Juan Fan; Xiang-Bo Wan; Xin-Hui Fu; Pei-Huang Wu; Dian-Ke Chen; Pu-Ning Wang; Li Jiang; Dao-Hai Wang; Zhi-Ting Chen; Yan Huang; Jian-Ping Wang; Lei Wang
Journal:  Tumour Biol       Date:  2014-07-24

4.  A new KSRP-binding compound suppresses distant metastasis of colorectal cancer by targeting the oncogenic KITENIN complex.

Authors:  Jeong A Bae; Woo Kyun Bae; Sung Jin Kim; Yoo-Seung Ko; Keon Young Kim; So-Yeon Park; Young Hyun Yu; Eun Ae Kim; Ik Joo Chung; Hangun Kim; Hyung-Ho Ha; Kyung Keun Kim
Journal:  Mol Cancer       Date:  2021-05-26       Impact factor: 27.401

5.  Prostaglandins in cancer cell adhesion, migration, and invasion.

Authors:  David G Menter; Raymond N Dubois
Journal:  Int J Cell Biol       Date:  2012-02-29

6.  KITENIN promotes glioma invasiveness and progression, associated with the induction of EMT and stemness markers.

Authors:  Kyung-Hwa Lee; Eun-Jung Ahn; Se-Jeong Oh; Ok Kim; Young-Eun Joo; Jeong-A Bae; Somy Yoon; Hyang-Hwa Ryu; Shin Jung; Kyung-Keun Kim; Jae-Hyuk Lee; Kyung-Sub Moon
Journal:  Oncotarget       Date:  2015-02-20

7.  Stage of breast cancer progression influences cellular response to activation of the WNT/planar cell polarity pathway.

Authors:  Connor D MacMillan; Hon S Leong; David W Dales; Amy E Robertson; John D Lewis; Ann F Chambers; Alan B Tuck
Journal:  Sci Rep       Date:  2014-09-10       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.